Governance Intellia Therapeutics, Inc.

NTLA

US45826J1051

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 02:58:27 2026-04-15 pm EDT			5-day change	1st Jan Change
14.73 ^USD	-0.34%		+5.66%	+63.01%

Mar. 06	Nektar Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
Mar. 03	Intellia Therapeutics Presents Longer-Term Clinical Data For Lonvoguran Ziclumeran	CI

Executive Committee: Intellia Therapeutics, Inc.

Manager

Positions heldSince

John Leonard

68 year

Chief Executive Officer	2017-12-31
President	2017-12-31

Marika St Amand

Human Resources Officer

Eliana Clark

69 year

Chief Tech/Sci/R&D Officer

2019-12-31

David Lebwohl

71 year

Chief Tech/Sci/R&D Officer

2020-04-29

James Basta

60 year

General Counsel	2021-06-23
Corporate Secretary	2021-06-23

Aron Stein

General Counsel

Michael Dube

48 year

Comptroller/Controller/Auditor

2024-04-09

Edward Dulac

51 year

Director of Finance/CFO	2024-07-21
Treasurer	2024-07-21

Birgit Schultes

63 year

Chief Tech/Sci/R&D Officer

2025-01-12

Composition of the Board of Directors: Intellia Therapeutics, Inc.

Director

CommitteesSince

Frank Verwiel

63 year

Compensation Committee	2019-12-31
Nominating Committee	2019-12-31
Audit Committee	2015-12-31
Governance Committee Chair
Nominating Committee Chair
Finance Committee	2015-12-31

William Chase

58 year

Audit Committee Chair	2024-06-20
Compensation Committee	2024-06-20
Governance Committee	2024-06-20
Nominating Committee	2024-06-20

Muna Bhanji

63 year

Governance Committee	2022-04-27
Nominating Committee	2022-04-27
Compensation Committee	2021-03-10
Audit Committee	2022-04-27

John Leonard

68 year

Audit Committee	2016-09-30
Governance Committee	2016-09-30
Nominating Committee	2016-09-30

Brian Goff

57 year

Compensation Committee	2024-06-12
HR Committee	2024-06-12

Georgia Keresty

64 year

Audit Committee	2021-04-08
Compensation Committee Chair

Fred Cohen

69 year

Compensation Committee	2013-12-31
HR Committee	2013-12-31

Jesse Goodman

74 year

Governance Committee	2018-10-30
Nominating Committee	2018-10-30

Latest Appointments: Intellia Therapeutics, Inc.

25-08-07	Intellia Therapeutics, Inc. Announces Retirement of David Lebwohl as Executive Vice President and Chief Medical Officer, Effective August 7, 2026	CI
25-05-19	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday After Moody's Downgrades US Credit Rating	MT
25-01-10	Intellia Therapeutics, Inc. Announces Executive Changes	CI
25-01-09	Intellia Therapeutics to Workforce by 27%, Halt Some Programs	MT
24-06-26	Intellia Therapeutics Names Edward Dulac CFO	MT
24-06-26	Intellia Therapeutics, Inc. Announces Executive Changes	CI
24-06-26	Intellia Therapeutics, Inc. Announces Chief Financial Officer Changes	CI

More news

Former Officers and Directors: Intellia Therapeutics, Inc.

Insider

Positions held

SinceUntil

Laura Sepp-Lorenzino

Chief Tech/Sci/R&D Officer

2019-05-27

2025-01-12

Glenn Goddard

Comptroller/Controller/Auditor	2018-10-28	2024-06-29
Director of Finance/CFO	2018-10-28	2024-06-29
Treasurer	2018-10-28	2024-06-29

John Crowley

Director/Board Member	2020-10-01	2023-12-04
Independent Dir/Board Member	2020-10-01	2023-12-04

Jean-Francois Formela

Director/Board Member	2014-04-30	2023-06-14
Founder	2014-04-30	2023-06-14
Independent Dir/Board Member	2014-04-30	2023-06-14

Caroline Dorsa

Director/Board Member	2015-12-13	2023-06-14
Independent Dir/Board Member	2015-12-13	2023-06-14

Christine Foster

Corporate Officer/Principal

2022-02-28

Derek Hicks

Corporate Officer/Principal

2021-12-19

Jose Rivera

Chief Operating Officer	2015-03-31	2016-12-31
General Counsel	2015-03-31	2021-06-23
Corporate Secretary	-	2021-06-23

Andrew Schiermeier

Chief Operating Officer	-	2021-06-20
Corporate Officer/Principal	2018-03-31	-

Jennifer Mound Smoter

Public Communications Contact

2015-07-31

2021-01-31

Perry Karsen

Director/Board Member	-	2020-12-30
Chairman	2016-03-31	-
Independent Dir/Board Member	2016-03-31	-

David V. Morrissey

Chief Tech/Sci/R&D Officer	2014-06-30	-
Corporate Officer/Principal	2014-06-30	2018-08-31

Graeme Bell

Comptroller/Controller/Auditor	2017-09-14	2018-08-02
Director of Finance/CFO	2016-12-11	2018-08-02

Nessan Bermingham

Director/Board Member	2014-04-30	2017-12-30
Chief Executive Officer	2014-04-30	2017-12-30
Founder	2014-04-30	2017-12-30
President	2014-04-30	2017-12-30

Nicole Heifner

Comptroller/Controller/Auditor

2017-09-14

Lindsey Trickett

Investor Relations Contact

2017-09-06

Moncef Slaoui

Director/Board Member

2017-07-23

2017-08-06

Carl Gordon

Director/Board Member	2015-07-31	2017-07-24
Independent Dir/Board Member	2015-07-31	2017-07-24

Jennifer King

Corporate Officer/Principal

2017-02-28

Sapna R. Srivastava

Director of Finance/CFO

2015-03-31

2016-12-11

Rachel Haurwitz

Director/Board Member	2014-06-30	2016-10-31
Founder	2014-06-30	2016-10-31

Thomas Barnes

Chief Tech/Sci/R&D Officer	2014-09-30	-
Corporate Officer/Principal	2014-09-30	-

Luciano Marraffini

Founder

2014-04-30

Erik Sontheimer

Founder

2014-04-30

Derrick J. Rossi

Founder

2014-04-30

Rodolphe Barrangou

Founder

2014-04-30

Andrew May

Director/Board Member	2014-04-30	-
Founder	2014-04-30	-

Jennifer Doudna

Founder

2009-12-31

Ian Karp

Public Communications Contact

Walter Strapps

Corporate Officer/Principal

Li Lina

Investor Relations Contact

Julie Ferguson

Public Communications Contact

Erin Schellhammer

Human Resources Officer

Walid Awni

Corporate Officer/Principal

Chau Khuong

Director/Board Member

Ellen Rohde

Corporate Officer/Principal

Age distribution of managers

Parity Men Women

Male	14
Female	2

Of which Executive Committee

Male	8
Female	1

Of which Directors

Male	7
Female	1

Revisions

Recommandations analystes

Évolution recommandations analystes 1 an

Évolution recommandations analystes 4 mois

Objectif analystes

Évolution objectif analystes 1 an

Évolution objectif analystes 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE) are the first CRISPR/Cas9-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. It is also developing ex vivo applications to address immuno-oncology and autoimmune diseases.

Employees

377

Sector

Biotechnology & Medical Research

More about the company